JP2003507473A - テロメラーゼインヒビターおよびその使用の方法 - Google Patents

テロメラーゼインヒビターおよびその使用の方法

Info

Publication number
JP2003507473A
JP2003507473A JP2001518671A JP2001518671A JP2003507473A JP 2003507473 A JP2003507473 A JP 2003507473A JP 2001518671 A JP2001518671 A JP 2001518671A JP 2001518671 A JP2001518671 A JP 2001518671A JP 2003507473 A JP2003507473 A JP 2003507473A
Authority
JP
Japan
Prior art keywords
compound
mmol
composition
thiazolidine
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001518671A
Other languages
English (en)
Japanese (ja)
Inventor
アリソン シー． チン，
ライアン ホルコーム，
ミークジスロウ エイ． ピアティスゼック，
アピンダー シン，
リチャード エル． トルマン，
勉 赤間
裕 神田
章良 浅井
順範 山下
香里 遠藤
弘之 山口
Original Assignee
ジェロン コーポレイション
協和醗酵工業株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP30757699A external-priority patent/JP2001072592A/ja
Application filed by ジェロン コーポレイション, 協和醗酵工業株式会社 filed Critical ジェロン コーポレイション
Publication of JP2003507473A publication Critical patent/JP2003507473A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2001518671A 1999-07-01 2000-06-30 テロメラーゼインヒビターおよびその使用の方法 Withdrawn JP2003507473A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US14217399P 1999-07-01 1999-07-01
JP11-187616 1999-07-01
JP18761699 1999-07-01
US60/142,173 1999-07-01
JP30757699A JP2001072592A (ja) 1999-07-01 1999-10-28 テロメラーゼ阻害剤
JP11-307576 1999-10-28
PCT/US2000/018211 WO2001002377A1 (fr) 1999-07-01 2000-06-30 Inhibiteurs de telomerase et leurs procedes d'utilisation

Publications (1)

Publication Number Publication Date
JP2003507473A true JP2003507473A (ja) 2003-02-25

Family

ID=27325921

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001518671A Withdrawn JP2003507473A (ja) 1999-07-01 2000-06-30 テロメラーゼインヒビターおよびその使用の方法

Country Status (9)

Country Link
EP (1) EP1109796A1 (fr)
JP (1) JP2003507473A (fr)
KR (1) KR20010099634A (fr)
CN (1) CN1321153A (fr)
AU (1) AU6340600A (fr)
CA (1) CA2341253A1 (fr)
HK (1) HK1043113A1 (fr)
ID (1) ID29875A (fr)
WO (1) WO2001002377A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008056660A (ja) * 2006-08-31 2008-03-13 Taipei Medical Univ インドールスルフォンアミド化合物
JP2010520307A (ja) * 2007-03-07 2010-06-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ エストロゲン関連受容体−アルファモジュレーターとしての置換フェノキシｎ−アルキル置換チアゾリジンジオン

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1376150A (zh) * 1999-07-26 2002-10-23 盐野义制药株式会社 具有血栓形成素受体拮抗作用的药物组合物
DE60115132T2 (de) * 2000-04-21 2006-07-06 Pfizer Products Inc., Groton Thyroid-Rezeptorliganden
US6620830B2 (en) 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
EP1276730A2 (fr) * 2000-04-24 2003-01-22 ARYx Therapeutics Compositions et methodes destinees au traitement du diabete, de l'hyperlipidemie, de l'hypercholesterolemie et de l'atherosclerose
US6958355B2 (en) 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6768008B2 (en) * 2000-04-24 2004-07-27 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6784199B2 (en) 2000-09-21 2004-08-31 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis in mammals
US6680387B2 (en) 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
DE10133665A1 (de) * 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
WO2003018011A1 (fr) 2001-08-24 2003-03-06 Wyeth Holdings Corporation 5-(substitue)-5-(substitue sulfonyl ou sulfanyl)thiazolidine-2,4-diones utiles pour l'inhibition de la farnesyl-proteine transferase
US7045523B2 (en) 2001-10-18 2006-05-16 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and telomerase inhibitor
GB0204252D0 (en) * 2002-02-23 2002-04-10 Oxford Glycosciences Uk Ltd Novel compounds
WO2004028535A1 (fr) * 2002-09-26 2004-04-08 Pintex Pharmaceuticals, Inc. Composes de modulation de pin-1 et leurs procedes d'utilisation
US7781464B2 (en) * 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
US6794401B2 (en) 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
US7521465B2 (en) 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
WO2004093803A2 (fr) * 2003-04-16 2004-11-04 Pintex Pharmaceuticals, Inc. Composes photochimiotherapeutiques utilises dans le traitement d'etats associes a pin1
US7087576B2 (en) 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
FI20041129A0 (fi) * 2004-08-30 2004-08-30 Ctt Cancer Targeting Tech Oy Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi
CA2580811C (fr) 2004-09-28 2014-04-08 Otsuka Pharmaceutical Co., Ltd. Derive de carbostyrile
FR2887444A1 (fr) * 2005-06-28 2006-12-29 Oreal Composes benzylidene-1,3-thiazolidine-2,4-diones, leurs utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute et/ou augmenter leur densite.
KR100814109B1 (ko) 2006-01-09 2008-03-14 한국생명공학연구원 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
EP2217235A4 (fr) * 2007-11-15 2011-01-12 Musc Found For Res Dev Inhibiteurs de protéines kinases pim, compositions et procédés pour traiter le cancer
TWI461423B (zh) * 2008-07-02 2014-11-21 Astrazeneca Ab 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物
CN101973893B (zh) * 2010-09-07 2013-07-17 黑龙江省科学院石油化学研究院 4-[2-(1-苯乙烯基)]-n,n-二(4-溴苯基)苯胺的合成方法
KR101817287B1 (ko) * 2016-01-08 2018-01-10 조선대학교 산학협력단 티아졸리딘디온 유도체 및 그의 용도
CN116217511B (zh) * 2023-03-22 2024-04-19 沈阳药科大学 一种双靶点化合物及其制备方法和在制备sEH抑制剂与PPARs激动剂中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS58118577A (ja) * 1982-01-07 1983-07-14 Takeda Chem Ind Ltd チアゾリジン誘導体
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4738972A (en) * 1985-05-21 1988-04-19 Pfizer Inc. Hypoglycemic thiazolidinediones
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
WO1989008650A1 (fr) * 1988-03-08 1989-09-21 Pfizer Inc. Agents hypoglycemiques de thiazolidinedione
WO1989008651A1 (fr) * 1988-03-08 1989-09-21 Pfizer Inc. Derives de thiaxolidinedione hypoglycemiques
IE940525L (en) * 1988-05-25 1989-11-25 Warner Lambert Co Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
US5143929A (en) * 1991-05-09 1992-09-01 Warner-Lambert Company 2-substituted thiazolidinone, oxazolidinone, and imidazolidinone derivatives of fenamates as antiinflammatory agents
US6251928B1 (en) * 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
US5814647A (en) * 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008056660A (ja) * 2006-08-31 2008-03-13 Taipei Medical Univ インドールスルフォンアミド化合物
JP4521428B2 (ja) * 2006-08-31 2010-08-11 台北醫學大學 インドールスルホンアミド化合物
JP2010520307A (ja) * 2007-03-07 2010-06-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ エストロゲン関連受容体−アルファモジュレーターとしての置換フェノキシｎ−アルキル置換チアゾリジンジオン

Also Published As

Publication number Publication date
CA2341253A1 (fr) 2001-01-11
WO2001002377A9 (fr) 2001-10-11
EP1109796A1 (fr) 2001-06-27
WO2001002377A1 (fr) 2001-01-11
HK1043113A1 (zh) 2002-09-06
CN1321153A (zh) 2001-11-07
AU6340600A (en) 2001-01-22
KR20010099634A (ko) 2001-11-09
ID29875A (id) 2001-10-18

Similar Documents

Publication Publication Date Title
JP2003507473A (ja) テロメラーゼインヒビターおよびその使用の方法
US6518268B1 (en) Telomerase inhibitors and methods of their use
US5863936A (en) Telomerase inhibitors
US5760062A (en) Telomerase inhibitors
Eswaran et al. New quinoline derivatives: Synthesis and investigation of antibacterial and antituberculosis properties
US5703116A (en) Telomerase Inhibitors
US6452014B1 (en) Telomerase inhibitors and methods of their use
US5767278A (en) Telomerase inhibitors
US5656638A (en) Telomerase inhibitors
US5770613A (en) Telomerase inhibitors
NZ328900A (en) Substituted phenyl or pyridyl substituted phenyl, benzo[b]furan or indolyl derivatives and medicaments
JPH09505055A (ja) サイトカイン媒介疾患治療用オキサゾール
TWI284645B (en) Heterobicyclic pyrazole derivatives as kinase inhibitors
EP1373253A1 (fr) Inhibiteurs de kinases dependantes des cyclines en tant qu'agent anticancereux
AU2002249389A1 (en) Inhibitors of cyclin dependent kinases as anti-cancer agent
CN109574936B (zh) 一种具有hdac6抑制活性的异羟肟酸类化合物及其应用
US6372742B1 (en) Substituted indole compounds and methods of their use
JP3086692B2 (ja) 抗炎症剤としてのフエナメート１，３，４‐チアジアゾール類および１，３，４‐オキサジアゾール類
JP4395073B2 (ja) キナゾリン−４−オン誘導体
WO1999065875A1 (fr) Inhibiteurs de la telomerase
CN109574920B (zh) 3-腈基-6环丙基吡啶类ido1抑制剂及其用途
US7563905B2 (en) Triazole derivatives and method of using the same to treat HIV infections
JP2005503376A (ja) インダゾールまたはインドール誘導体およびヒトの医療、より詳しくは癌の治療におけるそれらの使用
WO2002076397A2 (fr) Inhibiteurs de telomerase et leurs procedes d'utilisation
KR20200030466A (ko) 7-하이드록시-4H-티에노[3,2-b]피리딘-5-온 유도체 및 그의 용도

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20070904